Literature DB >> 22652293

Prostaglandin E2 promotes the nuclear accumulation of lymphoid enhancer factor-1 in poorly differentiated breast cancer cells.

Ioannis Stasinopoulos1, Tiffany Greenwood, Kristine Glunde, Zaver M Bhujwalla.   

Abstract

Products of the COX reaction are frequently elevated in solid tumors and their roles in the malignant phenotype have been extensively investigated. We have shown that COX-2 is essential for the growth of MDA-MB-231 cells in the fat pad of SCID mice and for their extrapulmonary colonization following injection in the tail vein of SCID mice. The molecular changes that follow shRNA-mediated silencing of COX-2 include a significant downregulation of LEF-1, a transcription factor normally activated during development following the Wnt-induced nuclear translocation of β-catenin. We also report that COX-2-silenced cells have reduced nuclear accumulation of LEF-1 protein and that the COX-2 product PGE(2) partially restored nuclear LEF-1 expression in COX-2-silenced cells. Further, we demonstrate that, like parental COX-2 containing MDA-MB-231 cells, COX-2-silenced cells maintain nuclear localization of β-catenin.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22652293      PMCID: PMC3429715          DOI: 10.1016/j.prostaglandins.2012.05.002

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  33 in total

1.  Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex.

Authors:  Thomas Kramps; Oliver Peter; Erich Brunner; Denise Nellen; Barbara Froesch; Sandipan Chatterjee; Maximilien Murone; Stephanie Züllig; Konrad Basler
Journal:  Cell       Date:  2002-04-05       Impact factor: 41.582

2.  Genome-wide pattern of TCF7L2/TCF4 chromatin occupancy in colorectal cancer cells.

Authors:  Pantelis Hatzis; Laurens G van der Flier; Marc A van Driel; Victor Guryev; Fiona Nielsen; Sergei Denissov; Isaäc J Nijman; Jan Koster; Evan E Santo; Willem Welboren; Rogier Versteeg; Edwin Cuppen; Marc van de Wetering; Hans Clevers; Hendrik G Stunnenberg
Journal:  Mol Cell Biol       Date:  2008-02-11       Impact factor: 4.272

3.  Chromatin-specific regulation of LEF-1-beta-catenin transcription activation and inhibition in vitro.

Authors:  A V Tutter; C J Fryer; K A Jones
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

4.  Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals.

Authors:  Xiaohui Xie; Jun Lu; E J Kulbokas; Todd R Golub; Vamsi Mootha; Kerstin Lindblad-Toh; Eric S Lander; Manolis Kellis
Journal:  Nature       Date:  2005-02-27       Impact factor: 49.962

Review 5.  Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force.

Authors:  Alaa Rostom; Catherine Dubé; Gabriela Lewin; Alexander Tsertsvadze; Nicholas Barrowman; Catherine Code; Margaret Sampson; David Moher
Journal:  Ann Intern Med       Date:  2007-03-06       Impact factor: 25.391

Review 6.  Gene expression profiling in breast cancer: classification, prognostication, and prediction.

Authors:  Jorge S Reis-Filho; Lajos Pusztai
Journal:  Lancet       Date:  2011-11-19       Impact factor: 79.321

7.  Identification of c-MYC as a target of the APC pathway.

Authors:  T C He; A B Sparks; C Rago; H Hermeking; L Zawel; L T da Costa; P J Morin; B Vogelstein; K W Kinzler
Journal:  Science       Date:  1998-09-04       Impact factor: 47.728

8.  A genome-wide screen for beta-catenin binding sites identifies a downstream enhancer element that controls c-Myc gene expression.

Authors:  Gregory S Yochum; Ryan Cleland; Richard H Goodman
Journal:  Mol Cell Biol       Date:  2008-10-13       Impact factor: 4.272

Review 9.  The role of LEF/TCF factors in neoplastic transformation.

Authors:  Amod Ravindranath; Angeline O'Connell; Patrick G Johnston; Mohamed K El-Tanani
Journal:  Curr Mol Med       Date:  2008-02       Impact factor: 2.222

10.  Inflammation, but not hypoxia, mediated HIF-1alpha activation depends on COX-2.

Authors:  Ioannis Stasinopoulos; David R O'Brien; Zaver M Bhujwalla
Journal:  Cancer Biol Ther       Date:  2009-01       Impact factor: 4.742

View more
  2 in total

1.  Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study.

Authors:  S Anthony Kahn; Christine M Mullin; Louis-Philippe de Lorimier; Kristine E Burgess; Rebecca E Risbon; Rogers M Fred; Kenneth Drobatz; Craig A Clifford
Journal:  Can Vet J       Date:  2013-03       Impact factor: 1.008

2.  COX-2 in cancer: Gordian knot or Achilles heel?

Authors:  Ioannis Stasinopoulos; Tariq Shah; Marie-France Penet; Balaji Krishnamachary; Zaver M Bhujwalla
Journal:  Front Pharmacol       Date:  2013-03-28       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.